ストックスクリーナーアプリを入手
30.96
0.16%
0.05
アフターアワーズ：
30.86
-0.10
-0.32%
Ideaya Biosciences Inc (IDYA) 最新ニュース
Ideaya Biosciences: Key Pivotal Data Imminent - Seeking Alpha
IDEAYA Biosciences, Inc. (IDYA) stock price, news, quote and history - Yahoo Finance UK
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), IDEAYA Biosciences (IDYA) and Bristol-Myers Squibb (BMY) - The Globe and Mail
IDEAYA Biosciences Advances IDE574 Into Phase 1 As First Patient Enrolled For KAT6 And KAT7 Dual Inhibitor - BioPharma APAC
IDEAYA Biosciences, Inc. (IDYA) Latest Stock News & Headlines - Yahoo Finance
IDEAYA Biosciences Target of Unusually Large Options Trading (NASDAQ:IDYA) - MarketBeat
Ideaya enrolls first patient in phase 1 trial of KAT6/7 inhibitor - Investing.com Canada
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer - TradingView
IDEAYA Biosciences announced that the first patient has been dosed in a Phase I clinical trial of Ide574, its potential first-in-class dual inhibitor targeting Kat6/7. - Bitget
IDYA PE Ratio & Valuation, Is IDYA Overvalued - Intellectia AI
Why IDEAYA Biosciences (IDYA) Is Up 7.5% After Early Data From First-in-Class Cancer Combo - Yahoo Finance
A Look At IDEAYA Biosciences (IDYA) Valuation After New DLL3 Combo Trial Progress And Early Responses - Yahoo Finance
IDEAYA Biosciences, Inc. $IDYA Position Decreased by JPMorgan Chase & Co. - MarketBeat
IDEAYA Biosciences Achieves 119.91% Growth, Establishing It as a Multibagger in Biotechnology Sector - Markets Mojo
IDYA Stock Price, Quote & Chart | IDEAYA BIOSCIENCES INC (NASDAQ:IDYA) - ChartMill
Block Trades: Does IDEAYA Biosciences Inc have a competitive edge2026 Key Highlights & Advanced Technical Analysis Signals - baoquankhu1.vn
Wedbush Reiterates Outperform Rating for IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat
37,595 Shares in IDEAYA Biosciences, Inc. $IDYA Acquired by Tudor Investment Corp ET AL - MarketBeat
Price-Driven Insight from (IDYA) for Rule-Based Strategy - Stock Traders Daily
IDEAYA begins combination trial of IDE849 and IDE161 cancer drugs By Investing.com - Investing.com Canada
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma – Company Announcemen - Financial Times
IDEAYA moves new cancer drug combo into patients after early lung tumor responses - Stock Titan
IDEAYA Biosciences Opens Weak with 5.14% Gap Down Amid Market Concerns - Markets Mojo
Vanguard disaggregates holdings; affiliates to report separately (IDYA) - stocktitan.net
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Finviz
IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA) and Incyte (INCY) - The Globe and Mail
Assessing IDEAYA Biosciences (IDYA) Valuation After Recent Share Price Weakness - simplywall.st
RBC Capital reiterates Ideaya Biosciences stock rating on trial delay By Investing.com - Investing.com Canada
RBC Capital reiterates Ideaya Biosciences stock rating on trial delay - Investing.com
Jefferies reiterates Ideaya Biosciences stock rating on trial delay By Investing.com - Investing.com Canada
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 6.1%Here's Why - marketbeat.com
IDEAYA Biosciences Sees Unusually High Options Volume (NASDAQ:IDYA) - marketbeat.com
Ideaya Biosciences stock maintained at Outperform by Mizuho on trial timing - Investing.com Canada
Citizens reiterates Ideaya Biosciences stock rating on mUM trial data By Investing.com - Investing.com Canada
Citizens reiterates Ideaya Biosciences stock rating on mUM trial data - Investing.com
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial - Sahm
IDEAYA delays darovasertib trial results to mid-April By Investing.com - Investing.com Canada
IDEAYA delays darovasertib trial results to mid-April - investing.com
IDEAYA Biosciences Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
(IDYA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Barclays Initiates Coverage of IDEAYA Biosciences (IDYA) with Overweight Recommendation - MSN
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and IDEAYA Biosciences (IDYA) - The Globe and Mail
IDEAYA Biosciences (IDYA) Gets a Buy from Mizuho Securities - The Globe and Mail
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs – Company Announcement - Financial Times
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
IDEAYA Biosciences, Inc. $IDYA Shares Purchased by Cinctive Capital Management LP - MarketBeat
Iron Triangle Partners LP Makes New Investment in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
A Look At IDEAYA Biosciences (IDYA) Valuation After IDE892 Trial Enrollment And Pipeline Refocus - simplywall.st
IDEAYA Biosciences, Inc. $IDYA Position Increased by Baker BROS. Advisors LP - MarketBeat
IDEAYA Biosciences Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
42,283 Shares in IDEAYA Biosciences, Inc. $IDYA Bought by WINTON GROUP Ltd - MarketBeat
Truist reiterates Ideaya Biosciences stock rating on MTAP program By Investing.com - Investing.com Canada
IDEAYA Biosciences: Expanding Precision Oncology Platform and Refocused MTAP Strategy Support Buy Rating - TipRanks
1.51%
1.75%
大文字化:
|
ボリューム (24 時間):